Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial
Posted inCardiology Diabetes & Endocrinology news

Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial

The ABILITY Diabetes Global trial demonstrates that the Abluminus DES+ sirolimus-eluting stent failed to meet non-inferiority compared to the XIENCE everolimus-eluting stent in patients with diabetes, showing significantly higher rates of target-lesion failure and revascularization at 12 months.
Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy
Posted inCardiology Clinical Updates news Specialties

Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy

Posthoc analysis of TWILIGHT shows that ischemic risk rises with the number of high‑risk features, bleeding does not, and ticagrelor monotherapy after 3 months reduces bleeding versus ticagrelor plus aspirin without increasing ischemic events across risk strata.